Senti Bio Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 91
Employees
  • Latest Deal Type
  • PIPE
  • (In Progress)
  • Latest Deal Amount
  • $66M
Latest Deal Amount
  • Investors
  • 37

Senti Bio General Information

Description

Developer of novel therapeutics designed to deliver more precise treatments. The company's therapeutics specialize in cell engineering and biological programming to build the future of gene and cell-based therapies, enabling physicians to give patients life-saving treatments at an affordable cost.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2 Corporate Drive
  • First Floor
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Senti Bio Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Senti Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. PIPE 20-Dec-2021 $66M 00000 In Progress Generating Revenue
8. Reverse Merger 20-Dec-2021 00000 00000 Announced Generating Revenue
7. Grant 28-Sep-2021 00.00 00000 Completed Generating Revenue
6. Later Stage VC (Series B) 06-Jan-2021 00000 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series C) 16-Jan-2019 00000 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 27-Feb-2018 0000 0000 0000 Completed Generating Revenue
3. Grant 01-Jan-2018 00000 Completed Generating Revenue
2. Grant 11-Aug-2016 $583K Completed Generating Revenue
1. Accelerator/Incubator 01-Aug-2016 Completed Generating Revenue
To view Senti Bio’s complete valuation and funding history, request access »

Senti Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Senti Bio’s complete cap table history, request access »

Senti Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapeutics designed to deliver more precise treatments. The company's therapeutics specialize in ce
Drug Discovery
South San Francisco, CA
91 As of 2021
00000
000000000 00000

0000000

eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
0000000000000
Berkeley, CA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

00000000

t enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo cons
0000000000000
Tucson, AZ
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Senti Bio Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Caribou Biosciences Formerly VC-backed Berkeley, CA 00 00000 00000000 00000
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
0000000 0000000000 Formerly VC-backed Brisbane, CA 000 0000 00000000 0000
000000000000 Private Equity-Backed London, United Kingdom 000 00000 000000000 00000
You’re viewing 5 of 52 competitors. Get the full list »

Senti Bio Patents

Senti Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3133333-A1 Chimeric receptors and methods of use thereof Pending 30-Apr-2019 000000000
US-20210299177-A1 Chimeric receptors and methods of use thereof Pending 30-Apr-2019 000000000
EP-3914702-A1 Fusion constructs for controlling protein function Pending 25-Jan-2019 000000000
AU-2019359890-A1 Combinatorial cancer immunotherapy Pending 17-Oct-2018 000000000
CA-3116138-A1 Combinatorial cancer immunotherapy Pending 17-Oct-2018 C12N15/85
To view Senti Bio’s complete patent history, request access »

Senti Bio Executive Team (9)

Name Title Board Seat Contact Info
Timothy Lu Ph.D Co-Founder, Chief Executive Officer & Board Member
Deborah Knobelman Ph.D Chief Financial Officer
Curt Herberts Chief Operating Officer
Philip Lee Ph.D Co-Founder & Chief Technology Officer
Wilson Wong Ph.D Scientific Co-Founder & Advisor
You’re viewing 5 of 9 executive team members. Get the full list »

Senti Bio Board Members (6)

Name Representing Role Since
Alex Kolicich 8VC Board Member 000 0000
Brenda Cooperstone MD Self Board Member 000 0000
Edward Mathers New Enterprise Associates Board Member 000 0000
Lee Cooper JD Leaps by Bayer Board Member 000 0000
Ran Geng Matrix Partners China Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Senti Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Senti Bio Investors (37)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Bayer Corporation Minority 000 0000 000000 0
Evolution VC Partners Venture Capital Minority 000 0000 000000 0
GRIDS Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 37 investors. Get the full list »

Senti Bio Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 20-Dec-2021 0000000000 Special Purpose Acquisition Company (SPAC) 0000000 0
Lexent Bio Early Stage VC Outcome Management (Healthcare)
To view Senti Bio’s complete investments and acquisitions history, request access »

Senti Bio Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 000 00000 00000 00 Completed
  • 5 buyers
To view Senti Bio’s complete exits history, request access »